19 / 27
…with special relevance
in selected high risk populations
• OS improved significantly in older patients (>65 y) treated with
lenvatinib vs those who received placebo
Brose MS, et al. J Clin Oncol. 2017.
Until the publication of these
analyses
, no other MKI has
demonstrated a significant OS
increase
in any given RR-DTC
population